恩扎卢胺单药治疗高危生化复发前列腺癌:EMBARK试验次要终点
EMBARK 3期试验二次分析比较恩扎卢胺单药与单用亮丙瑞林治疗高危生化复发前列腺癌。
要点
- 恩扎卢胺单药5年总生存率89.5%,单用亮丙瑞林87.2%
- 停药后两组多数患者后续接受激素治疗
核心结论
- 次要终点结果支持恩扎卢胺单药作为高危生化复发患者改善疗效并保留性健康的潜在选择。
研究设计与样本
- 3期EMBARK试验事后分析,患者按1:1:1随机分配至恩扎卢胺联合亮丙瑞林、单用亮丙瑞林或恩扎卢胺单药。
主要发现
- 恩扎卢胺单药 vs 单用亮丙瑞林的5年概率(95%CI):总生存89.5%(85.6-92.4) vs 87.2%(83.0-90.4)。
- 无远处转移生存86.8%(82.3-90.2) vs 81.5%(76.3-85.7);无症状进展66.6%(61.2-71.4) vs 53.3%(47.6-58.6)。
- 无首次症状性骨骼事件95.8%(92.9-97.6) vs 91.5%(87.8-94.1)。
- 停药后5年无任何激素治疗重启概率:单用亮丙瑞林7.8%(4.4-12.3) vs 恩扎卢胺单药5.6%(3.3-8.8)。
临床怎么用
- 对高危生化复发前列腺癌患者,恩扎卢胺单药可考虑作为保留性功能且不劣于亮丙瑞林的替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Primary analysis of the phase 3 EMBARK trial reported efficacy and safety outcomes for enzalutamide monotherapy in patients with high-risk biochemical recurrence. Here, we report secondary end points for enzalutamide monotherapy vs leuprolide alone. MATERIALS AND METHODS: Patients were randomized (1:1:1) to enzalutamide plus leuprolide, leuprolide alone, or enzalutamide monotherapy. Overall survival was a key secondary end point; non-key secondary end points were time to: distant metastasis, symptomatic progression, first symptomatic skeletal event, and resumption of any hormonal therapy. Sexual health was assessed using the Quality of Life Questionnaire-Prostate 25. Time-to-event end points were summarized using Kaplan-Meier methods with nominal P values. RESULTS: Five-year probability rates (95% CI) for enzalutamide monotherapy vs leuprolide alone were: overall survival, 89.5% (85.6-92.4) vs 87.2% (83.0-90.4); time to remaining free from distant metastasis, 86.8% (82.3-90.2) vs 81.5% (76.3-85.7); symptomatic progression, 66.6% (61.2-71.4) vs 53.3% (47.6-58.6); and first symptomatic skeletal event, 95.8% (92.9-97.6) vs 91.5% (87.8-94.1). After treatment suspension, the 5-year probability rate (95% CI) of remaining free from resumption of any hormonal therapy for leuprolide alone vs enzalutamide monotherapy was 7.8% (4.4-12.3) vs 5.6% (3.3-8.8). Sexual health was better preserved in patients treated with enzalutamide monotherapy than leuprolide alone (HR 0.76; 95% CI: 0.62-0.94; P = .008). After discontinuation, most patients were subsequently treated with hormonal therapies in both groups. CONCLUSIONS: Secondary end point results support enzalutamide monotherapy as a potential option to improve efficacy and preserve sexual health vs leuprolide alone for patients with high-risk biochemical recurrence. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02319837.
引用
- Shore ND, De Giorgi U, Tutrone RF, et al. Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points. J Urol. 2025. PMID: 41349040. doi:10.1097/JU.0000000000004879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。